Is this chronic systolic congestive heart failure, given a recent echocardiogram showing a left ventricular ejection fraction of 20–25%?

Yes, this is chronic systolic heart failure with severely reduced ejection fraction

An LVEF of 20-25% definitively confirms chronic systolic heart failure with reduced ejection fraction (HFrEF), placing this patient in the highest-risk category requiring immediate initiation of comprehensive guideline-directed medical therapy and evaluation for device interventions. 1

Classification and Severity

• HFrEF is defined as LVEF ≤40%, and this patient's LVEF of 20-25% falls well below that threshold, representing severe systolic dysfunction. 1

• The term "chronic" indicates this is not a new diagnosis—the patient has established structural cardiac abnormalities with progressive left ventricular dilatation and adverse cardiac remodeling. 2, 3

• An LVEF of 20-25% carries extremely high mortality risk: patients with LVEF ≤35% have >25% annual progression to cardiac symptoms if asymptomatic, and >10% annual mortality if symptomatic. 1

• Research demonstrates that once LVEF falls below 20%, the absolute ejection fraction value loses some prognostic discrimination—at this severity, functional capacity (peak VO2) becomes a stronger predictor than small differences in EF. 4 However, the ≤35% threshold remains critical for treatment decisions.

Immediate Management Priorities

Foundational Pharmacotherapy (Must Start All Four Classes)

• Beta-blocker: Initiate bisoprolol, carvedilol, or metoprolol succinate at low dose and titrate upward every 2 weeks while monitoring heart rate, blood pressure, and clinical status. 1, 5

• ACE inhibitor or ARNI: Start an ACE inhibitor (or sacubitril/valsartan if already on stable ACE inhibitor dose) 1-2 weeks after beta-blocker initiation to reduce morbidity and mortality. 5, 2

  • If ACE inhibitor is not tolerated, switch to an angiotensin receptor blocker (ARB). 1, 5
  • If both ACE inhibitor and ARB are intolerable, prescribe hydralazine plus nitrate combination. 1, 5

• Mineralocorticoid receptor antagonist (MRA): Add spironolactone or eplerenone for patients with LVEF <35% who remain symptomatic (NYHA class II-IV) despite initial therapy. 5, 6

  • Monitor serum potassium and renal function closely after initiation and dose adjustments. 5, 6

• SGLT2 inhibitor: Initiate dapagliflozin or empagliflozin regardless of diabetes status, as these agents significantly reduce cardiovascular and all-cause mortality across the entire LVEF spectrum. 2, 7

Diuretic Therapy for Congestion

• Loop diuretics are essential for relieving fluid overload and controlling symptoms, though they do not confer survival benefit. 5

• Assess volume status, orthostatic blood pressure changes, and daily weight to guide diuretic dosing. 5

Device Therapy Evaluation (Critical at LVEF 20-25%)

• Implantable cardioverter-defibrillator (ICD): This patient meets criteria for primary prevention ICD with LVEF ≤35%, particularly if ischemic etiology or QRS ≥120 ms with LVEF <30%. 5, 6

  • The ICD mortality benefit increases as EF decreases below 35%: patients with EF <30% show larger mortality reductions (HR 0.72) compared to EF 30-35% (HR 0.83). 6
  • Do not delay device evaluation while optimizing medical therapy—these interventions should proceed in parallel. 6

• Cardiac resynchronization therapy (CRT): Evaluate if QRS duration is ≥150 ms with LBBB morphology (Class I indication without need for dyssynchrony assessment). 8, 5

  • For QRS 120-149 ms with LBBB, echocardiographic mechanical dyssynchrony assessment may support CRT candidacy. 8, 5
  • Do not implant CRT if QRS <120 ms, regardless of mechanical dyssynchrony findings—trials showed lack of benefit and potential harm. 8

Prognostic Considerations

• Five-year survival after hospitalization for HFrEF is only 25%, underscoring the urgency of comprehensive intervention. 2

• LVEF remains an independent predictor of all-cause and cardiovascular mortality in chronic systolic HF, with the 35% cutoff showing better risk stratification accuracy than the 40% cutoff. 9

• Natriuretic peptide levels (BNP or NT-proBNP) should be measured to confirm diagnosis, assess severity, and guide therapy titration. 1

Common Pitfalls to Avoid

• Do not withhold beta-blockers in older adults (≥65 years) or those with comorbidities such as peripheral vascular disease, diabetes, COPD, or erectile dysfunction—evidence supports benefit across these groups. 1, 5

• Avoid nondihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with LVEF ≤35%, as they have negative inotropic effects and may worsen outcomes. 6

• Do not prematurely switch from ACE inhibitor to ARB without an adequate trial of ACE inhibitor therapy. 5

• Recognize that this patient is not "borderline"—LVEF of 20-25% meets validated thresholds for high-risk interventions based on robust trial data. 6

Monitoring and Follow-Up

• After each medication dose change, assess heart rate, blood pressure, and overall clinical status to ensure tolerability. 5

• Offer supervised cardiac rehabilitation to all stable patients, as structured exercise programs reduce hospital admissions and improve long-term quality of life. 5

• Serial echocardiography is indicated to monitor LV size, function, and response to therapy in patients with severe HFrEF. 1